celecoxib has been researched along with Astrocytoma in 3 studies
Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Excerpt | Relevance | Reference |
---|---|---|
"This study reports evidence for new targets and synergistic effect of celecoxib/fluvastatin combination in pilocytic astrocytoma." | 7.79 | Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. ( André, N; Baeza-Kallee, N; Carré, M; Chappé, C; Colin, C; Fernandez, C; Figarella-Branger, D; Lambert, S; Mercurio, S; Padovani, L; Scavarda, D; Tchoghandjian, A, 2013) |
"This study reports evidence for new targets and synergistic effect of celecoxib/fluvastatin combination in pilocytic astrocytoma." | 3.79 | Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. ( André, N; Baeza-Kallee, N; Carré, M; Chappé, C; Colin, C; Fernandez, C; Figarella-Branger, D; Lambert, S; Mercurio, S; Padovani, L; Scavarda, D; Tchoghandjian, A, 2013) |
" Here, we report on celecoxib desensitization after a celecoxib-induced skin reaction, thereby allowing the continuation of temozolomide/celecoxib chemotherapy in a young patient with recurrent astrocytoma." | 3.78 | Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction. ( Burbach, GJ; Vajkoczy, P; Zuberbier, T, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mercurio, S | 1 |
Padovani, L | 1 |
Colin, C | 1 |
Carré, M | 1 |
Tchoghandjian, A | 1 |
Scavarda, D | 1 |
Lambert, S | 1 |
Baeza-Kallee, N | 1 |
Fernandez, C | 1 |
Chappé, C | 1 |
André, N | 1 |
Figarella-Branger, D | 1 |
Hauser, P | 1 |
Vancsó, I | 1 |
Pócza, T | 1 |
Schuler, D | 1 |
Garami, M | 1 |
Burbach, GJ | 1 |
Vajkoczy, P | 1 |
Zuberbier, T | 1 |
3 other studies available for celecoxib and Astrocytoma
Article | Year |
---|---|
Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; CD36 Antigens; Celecox | 2013 |
[Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule].
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera | 2013 |
Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Celecoxib; Cyclooxygenase 2 Inhibitors; Dacar | 2012 |